References
- Gonzalez YM, Ghaly ES. (2010). Modified drug release of poloxamer matrix by including water-soluble and water insoluble polymer. Drug Dev Ind Pharm, 36(1):64–71.
- Zhang G, Pinnamaraju P, Ali M. (2001). Water insoluble polymer based sustained release formulation. US Patent 6251430, 26 Jun.
- FDA. (1997). Guidance for industry: Extended release oral dosage forms—Development, evaluation, and application of in vitro/in vivo correlations.
- Sande SA, Dyrstad K. (2002). A formulation development strategy for multivariate kinetic responses. Drug Dev Ind Pharm, 28(5):583–91.
- Sirisuth N, Augsburger L, Eddington N. (2002). Development and validation of a non-linear IVIVC model for diltiazem extended release formulations. Biopharm Drug Dispos, 23:1–8.
- Reynolds J. (1996). Martindale—The extra pharmacopoeia. 31st ed. London, UK: Royal Pharmaceutical Society of Great Britain, 924.
- Fatemi M, Gharaghani S. (2007). A novel QSAR model for prediction of apoptosis-inducing activity of 4-aryl-4-H-chromenes based on support vector machine. Bioorg Med Chem, 15:7746–54.
- Zhao CY, Zhang HX, Zhang XY, Liu MC, Hu ZD, Fan BT. (2006). Application of support vector machine (SVM) for prediction toxic activity of different data sets. Toxicology, 217:105–19.
- Kipouros K, Kachrimanis K, Nikolakakis I, Tserki V, Malamataris S. (2006). Simultaneous quantification of carbamazepine crystal forms in ternary mixtures (I, III, and IV) by diffuse reflectance FTIR spectroscopy (DRIFTS) and multivariate calibration. J Pharm Sci, 95:2419–31.
- Smola AJ, Schölkopf B. (1998). A tutorial on support vector regression, NeuroCOLT technical report NC-TR-98-030, Royal Holloway College, University of London, UK. http://www.kernel-machines.org/[accessed June 10, 2009].
- FDA. (2004). Guidance for industry. PAT—A framework for innovative pharmaceutical development, manufacturing, and quality assurance.
- FDA. (2006). Guidance for industry. Quality systems approach to pharmaceutical GMP regulations.
- ICH. (2009). International conference on harmonization (ICH) proceedings, Q8(R2). Pharmaceutical Development, US FDA Federal Register, Alameda, CA.
- USP. (2008). United States Pharmacopeia 31/National Formulary 26. Rockwell, MD: The United States Pharmaceutical Convention Inc.
- Montgomery DC. (1996). Design and analysis of experiments. 4th ed. New York: Wiley, 436–40.
- Burges CJ. (1998). A tutorial on support vector machines for pattern recognition. Data Min Knowl Discov, 2:121–67.
- Kecman V. (2001). Learning and soft computing: Support vector machine, neural networks, and fuzzy logic models, Massachusetts: The MIT press.
- Ibric S, Jovanovic M, Djuric Z, Paroj3ic J, Solomun L. (2002). The application of generalized regression neural network in the modeling and optimization of aspirin extended release tablets with Eudragit® RS PO as matrix substance. J Control Release, 82:213–22.
- Sathe P, Venitz J. (2003). Comparison of neural network and multiple linear regression as dissolution predictors. Drug Dev Ind Pharm, 29:349–55.
- Xu L, Wencong L, Shengli J, Yawei L, Nianyi C. (2006). Support vector regression applied to materials optimization of sialon ceramics. Chemom Intell Lab Syst, 82: 8–14.
- Zhou YP, Jiang JH, Lin WQ, Zou HY, Wu HL, Shen GL, . (2006). Boosting support vector regression in QSAR studies of bioactivities of chemical compounds. Eur J Pharm Sci, 28:344–53.
- Yu K, Cheng Y. (2007). Machine learning techniques for the prediction of the peptide mobility in capillary zone electrophoresis. Talanta, 71:676–82.
- Hadjmohammadi M, Kamel K. (2008). Response surface methodology and support vector machine for the optimization of separation in linear gradient elution. J Sep Sci, 31:3864–70.